SWOG clinical trial number
SWOG-8617

Evaluation of Interleukin 2 (rIL-2) in Metastatic Renal Cell Carcinoma

Closed
Phase
Published
Abbreviated Title
Evaluation of Interleukin 2 (rIL-2) in Metastatic Renal Cell Carcinoma
Activated
03/15/1987
Closed
08/15/1988

Publication Information Expand/Collapse

1992

Prognostic factors in patients with advanced renal cell carcinoma (RCC): The Southwest Oncology Group experience.

ME Marshall;P Goodman;P Kuebler;R Flanigan;ED Crawford ASCO 11:206(#638)

1990

Phase II trial of high dose intermittent interleukin-2 in metastatic renal cell carcinoma: A Southwest Oncology Group study.

RM Bukowski;P Goodman;ED Crawford;JS Sergi;BG Redman;RP Whitehead JNCI 82(3):143-146

1989

Phase II evaluation of recombinant interleukin-2 rIL-2) inmetastatic renal cell carcinoma (RCC):SWOG-8617

RM Bukowski;P Goodman;ED Crawford;JS Sergi;L Baker;J Neidhart ASCO 8:143(#556)